Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Surviv

		HER2 Support Group Forums > Breast Cancer Newsfeed
Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Surviv

10-31-2009, 04:11 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 18,983	Global Phase III Study Results Show Eribulin Meets Primary Endpoint Of Overall Surviv Eisai Inc. announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer. More...

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Forum Rules

All times are GMT -7. The time now is 12:40 PM.